AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 10, 2026, 4:05 PM ET Nuvation Bio to present at the Jefferies Global Healthcare Conference in London on November 17, 2026. AI-generated summary · Source: company release
NYSE: $NUVBBiotech · Precision oncologyCommercial growth, glioma trials and dilution

NUVB Stock Hub: Nuvation Bio News, IBTROZI and Safusidenib

IBTROZI Q3 U.S. net product sales were $27.457M, separate from $17.494M collaboration and license revenue. The supplemental label update was already approved in September; January 4, 2027 is a superseded action-date target. Safusidenib data and trial-overview posters are scheduled for November 13. Q3 2026 Form 10-Q · November 4 IBTROZI supplemental application approval · September 17, 2026 SNO poster schedule · November 2, 2026

Last updated: November 12, 2026Market data: November 11, 2026 regular closeFinancial period: September 30, 2026Currency: USD
Research Library · Biotech
Nuvation Bio: IBTROZI Growth and the Safusidenib Glioma Program
ROS1 commercial growth, glioma evidence, funding and retained economics · November 12, 2026
Get the report (PDF)
Next catalyst · Announced scientific poster session
November 13, 2026 · SNO posters, 19:30–21:30 New York

Four safusidenib posters are scheduled in Philadelphia: additional updated J201 Phase 2 results and three trial-in-progress overviews. The SNO meeting runs November 12–15; the company poster session is specifically November 13. SNO poster schedule · November 2, 2026

Jefferies follows November 17 at 14:30 London / 09:30 New York. The IBTROZI supplemental application is already approved, rather than awaiting the former January 2027 goal date. Jefferies London announcement · November 10, 2026 IBTROZI supplemental application approval · September 17, 2026
NUVB daily price chart
Daily chart · Finviz (affiliate link on click). Explore NUVB on JC Just Charts.

NUVB stock data: financial position and capital

Regular close
$4.29
November 11, 2026 · completed regular session
Common-stock value
$1.514B
Calculated from 353,017,638 October 30 common shares
Cash and securities
$663.370M
September 30, 2026
Q3 U.S. product revenue
$27.457M
IBTROZI net sales
Q3 collaboration / license revenue
$17.494M
Separate from U.S. product sales
Q3 net loss
$(41.899)M
Quarter ended September 30
Nine-month operating cash use
$76.461M
January–September 2026
Convertible principal
$287.5M
Includes July overallotment · maturity July 2032

Cash already includes the July note-overallotment proceeds. The cover count includes Class A and Class B common stock; it is not the public float or a fully diluted count. Royalties payable to Sagard and existing licenses affect retained economics. Q3 2026 Form 10-Q · November 4

IBTROZI adoption funds a broader glioma development plan

IBTROZI is approved, while safusidenib remains investigational. A single-arm J201 response signal and a Fast Track designation do not establish randomized superiority or FDA approval. The updated label duration result belongs to TRUST-I and is not a new indication. IBTROZI prescribing information · September 2026 Safusidenib Phase 2 update and new trials · July 20, 2026 Safusidenib Fast Track designation · August 20, 2026 IBTROZI supplemental application approval · September 17, 2026

▲ The constructive case

Growing U.S. IBTROZI sales, longer observed response duration and international partners support the commercial base. Safusidenib provides separate development opportunities across glioma populations, with SNO information and ongoing controlled trials. Q3 results and business update · November 4, 2026 SNO poster schedule · November 2, 2026 Corporate presentation · November 4, 2026

▼ The cautious case

Sales remain concentrated in one U.S. product, while collaborations include nonrecurring milestones and licensing items. Glioma evidence is still developing; options, notes, financing rights and licenses reduce the common-holder claim on future success. Q3 2026 Form 10-Q · November 4 Q3 results and business update · November 4, 2026

Latest NUVB news

Nov 10, 2026

Nuvation Bio to present at the Jefferies Global Healthcare Conference in London

David Hung, M.D., Founder, President and CEO, and Philippe Sauvage, CFO, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Tuesday, November 17, 2026. A live webcast will be available on the Investor Relations section of the Nuvation Bio website. An archived recording will be available for 90 days following each event.

Company release · PR Newswire

NUVB stock catalysts: SNO data, commercial progress and separate trial windows

SNO begins November 12, but the announced company session is November 13. ClinicalTrials.gov completion dates are operating estimates and differ from public disclosure targets. January 4, 2027 is no longer a pending IBTROZI sNDA decision. SNO poster schedule · November 2, 2026 IBTROZI supplemental application approval · September 17, 2026

IBTROZI and safusidenib: commercial and clinical evidence

IBTROZI is approved for adult locally advanced or metastatic ROS1-positive NSCLC. The September label update includes TRUST-I median response duration of 49.7 months in TKI-naïve patients; it does not approve safusidenib. The glioma candidate remains investigational across distinct low- and high-grade populations. IBTROZI prescribing information · September 2026 IBTROZI supplemental application approval · September 17, 2026 Safusidenib Phase 2 update and new trials · July 20, 2026

NUVB earnings, dilution and retained economics

Q3 total revenue was $44.951M: $27.457M product revenue and $17.494M collaboration/license revenue. September resources were $663.370M; nine-month operating cash use was $76.461M. The $287.5M convertible notes, employee awards and Sagard sales-linked obligations are separate claims. Q3 2026 Form 10-Q · November 4

Merlintrader Health Score · NUVB

3.60out of 5
Financial position4.0

September cash and securities were $663.370M, including completed note financing. Nine-month operating cash use was $76.461M; sales-linked liabilities and notes remain relevant. Q3 2026 Form 10-Q · November 4

Catalysts4.0

SNO posters are scheduled November 13 and Jefferies November 17. Longer-term glioma trials are distinct from the already approved IBTROZI label update. SNO poster schedule · November 2, 2026 Jefferies London announcement · November 10, 2026 IBTROZI supplemental application approval · September 17, 2026

Dilution2.5

September options include 78,229,809 Class A and 2,000,000 Class B options, plus RSUs and $287.5M convertible principal. Full-principal conversion differs from the historical EPS assumption. Q3 2026 Form 10-Q · November 4

Trading liquidity3.0

NUVB is listed on the NYSE. October 30 common shares totaled 353,017,638 across classes; the count is not freely traded float. Clinical and commercial news can produce gaps. Q3 2026 Form 10-Q · November 4

Execution4.0

Q3 U.S. IBTROZI net sales grew to $27.457M and the updated label was approved. Safusidenib still requires further evidence, including controlled studies. Q3 results and business update · November 4, 2026 IBTROZI supplemental application approval · September 17, 2026

Weighted calculation: 4.0 × 30% + 4.0 × 30% + 2.5 × 20% + 3.0 × 10% + 4.0 × 10% = 3.60 out of 5. Editorial assessment dated November 12, 2026. Weights: financial position 30%, catalysts 30%, dilution 20%, trading liquidity 10%, execution 10%. Not an investment recommendation or probability of approval.

NUVB red flags

NUVB Stock FAQ: Nuvation Bio Questions Answered

What is the next NUVB stock catalyst for Nuvation Bio?

As of November 12, 2026, four safusidenib posters were scheduled at SNO on November 13, 19:30–21:30 New York. One concerns additional updated J201 Phase 2 results; three describe trials in progress. Jefferies follows November 17 at 09:30 New York / 14:30 London. SNO poster schedule · November 2, 2026 Jefferies London announcement · November 10, 2026

Is NUVB IBTROZI approved, and is January 2027 still a pending decision?

IBTROZI received initial U.S. approval June 11, 2025 for advanced ROS1-positive NSCLC. In September 2026, FDA approved the supplemental label update ahead of its January 4, 2027 target date. That former date is no longer a pending decision; safusidenib remains investigational. FDA initial taletrectinib approval · June 11, 2025 IBTROZI supplemental application approval · September 17, 2026

How much cash does Nuvation Bio have for NUVB operations?

At September 30, 2026, cash and equivalents of $153.766M plus marketable securities of $509.604M totaled $663.370M. That balance already includes July convertible overallotment proceeds. Nine-month operating cash use was $76.461M; the resource balance is distinct from net cash after all financing claims. Q3 2026 Form 10-Q · November 4

What are NUVB share dilution risks?

At September 30, 2026, Nuvation Bio had 78,229,809 Class A options, 2,000,000 Class B options and 3,814,301 RSUs. The full $287.5M convertible principal initially corresponds to approximately 36.655M Class A shares, subject to terms and settlement. These instruments are separate from outstanding common stock. Q3 2026 Form 10-Q · November 4

What were Nuvation Bio’s latest earnings for NUVB?

For Q3 ended September 30, 2026, Nuvation Bio reported $44.951M total revenue, comprising $27.457M U.S. product sales and $17.494M collaboration/license revenue. Net loss was $41.899M. Product demand and one-time licensing or milestone revenue require separate interpretation. Q3 2026 Form 10-Q · November 4 Q3 results and business update · November 4, 2026

What does Nuvation Bio do for NUVB holders?

As of November 12, 2026, Nuvation Bio commercializes IBTROZI in the U.S. and develops oncology therapies including safusidenib for IDH1-mutant glioma. International partners commercialize taletrectinib in licensed territories, while the drug-drug-conjugate platform is evaluating preclinical candidates. Q3 2026 Form 10-Q · November 4 Q3 results and business update · November 4, 2026 Corporate presentation · November 4, 2026

What changed in the NUVB IBTROZI label?

In September 2026, the approved label update added median duration of response of 49.7 months in TKI-naïve TRUST-I patients, with 51 months median follow-up. This result belongs to that study population. The company reported no changes to the label safety sections. IBTROZI supplemental application approval · September 17, 2026 IBTROZI prescribing information · September 2026

What evidence supports NUVB safusidenib before SNO?

In July 2026, the company reported J201 centrally assessed ORR of 51.9% in twenty-seven chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutant glioma patients. Median PFS was not reached and 36-month PFS was 79.1%. The uncontrolled study supports further development, while SNO additional results are a separate scheduled update. Safusidenib Phase 2 update and new trials · July 20, 2026 SNO poster schedule · November 2, 2026

Primary sources

Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $NUVB or any other security.

Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases, ClinicalTrials.gov and market data, and are stated with their reference dates. Data can change without notice. Readers should verify every figure against the primary source before acting on it.

Clinical-stage biotechnology companies carry high execution, regulatory and financing risk. Trials fail, endpoints miss, enrollment slips, regulators ask for more data or decline to file an application, and companies that spend ahead of revenue raise equity at whatever price the market will bear. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate. Investors may lose part or all of their capital.

Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.

Trending now

Bright illustration of blood cells, medicines and molecular structures for hereditary angioedema research.
BioCryst $BCRX $IONS $TAK $NTLA: HAE Treatment Choices
Colorful minerals and processing infrastructure illustrating rare-earth co-product economics.
Ramaco $METC $AREC $NB $UUUU: Rare Earth Economics
Colorful semiconductor memory stack and inspection equipment illustrating the AI memory supply chain.
Micron $MU, $RMBS, $AMKR, $CAMT: AI Memory Economics
LNG carrier, onshore facility and floating liquefaction vessel in a sunlit coastal scene.
Cheniere $LNG $VG $NEXT $GLNG: Four LNG Business Models